Highlights,Institutional investors such as Rhumbline Advisers adjusted their stake, reducing shares in the last ...

Following a lackluster 2024, shares of major drugmakers kicked off 2025 with an upbeat quarterly results reading. U.S. pharmaceuticals like Eli Lilly (LLY), Johnson & Johnson (JNJ), Bristol-Myers ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Gold Spot US Dollar, Gold Futures, VanEck Gold Miners ETF. Read Stewart Thomson's latest article on Investing.com ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolioThe company holds one of th ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

To come up with last week’s worst performers, we considered only the stocks with at least $2 billion in market capitalization ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...